Stock ABEO ABEONA THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Abeona Therapeutics Inc.

Equities

ABEO

US00289Y2063

Market Closed - Nasdaq
Other stock markets
 16:15:00 2024-05-03 EDT 		5-day change 1st Jan Change
4.6 USD +13.02% Intraday chart for Abeona Therapeutics Inc. +41.10% -8.18%
05-03 Abeona Therapeutics Prices $75 Million Securities Offering; Shares Rise MT
04-23 Sector Update: Health Care Stocks Rise Late Afternoon MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Abeona Therapeutics Prices $75 Million Securities Offering; Shares Rise
Sector Update: Health Care Stocks Rise Late Afternoon
Top Midday Decliners
US FDA declines to approve Abeona's skin disorder treatment
Abeona Therapeutics Inc. Provides Regulatory Update on Pz-Cel
Sector Update: Health Care Stocks Edge Up Late Monday Afternoon
Sector Update: Health Care Stocks Rise Monday Afternoon
Sector Update: Health Care
Abeona Therapeutics Shares Fall After 2023 Results, FDA Observations on Cleveland Facility
Abeona Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Abeona Says FDA Confirms Target Action Date For Pz-cel Application After Inspection
Sector Update: Health Care Stocks Ease in Late Afternoon
Sector Update: Health Care Stocks Softer Monday Afternoon
Abeona Therapeutics Says FDA Grants Priority Review for BLA to Treat Rare Connective Tissue Disorder; Shares Jump
Abeona Therapeutics Says FDA Grants Priority Review for BLA for Treatment of Rare Connective Tissue Disorder
Abeona Therapeutics Inc. Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application
Abeona Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Abeona Therapeutics Seeks FDA Priority Review for Potential Treatment of Recessive Dystrophic Epidermolysis Bullosa
Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa
Abeona Therapeutics Inc. Appoints Madhav Vasanthavada as Chief Commercial Officer
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ABEO Stock
  4. News Abeona Therapeutics Inc.
  5. Other languages